Liposarcoma
Drug research and approvals for liposarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 37 studies of liposarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 37
- Trials authorized in Canada: 6
- FDA orphan approvals: 2
- EU medicines: 0
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaNCT07741877 · Phase 2 · Iovance Biotherapeutics, Inc. · starts Oct 2, 2026
- Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsNCT07432932 · Not reported · Royal Marsden NHS Foundation Trust · starts Nov 19, 2021
- Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaNCT07377747 · Not reported · Australia and New Zealand Sarcoma Association · starts Sep 5, 2024
- N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive…NCT07261657 · Early Phase 1 · Seth Pollack · starts Apr 13, 2026
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.NCT07173972 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaNCT07169344 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific…NCT07148050 · Phase 1 · Seattle Children's Hospital · starts Dec 22, 2025
- A Study of Pembrolizumab in People With Ultra-Rare SarcomasNCT07089992 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Dec 4, 2025
- STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in…NCT06975293 · Phase 1 / Phase 2 · STORM Therapeutics LTD · starts May 5, 2025
Approved 2
- TrabectedinDNA inhibitor
- EribulinTubulin inhibitor
Phase 3 5
- AbemaciclibCyclin-dependent kinase 4 inhibitor
- Brigimadlin
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IfosfamideDNA inhibitor
- Milademetan
Phase 2 12 of 20
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- RibociclibCyclin-dependent kinase 4 inhibitor
- CabazitaxelTubulin inhibitor
- PioglitazoneMyxoid liposarcoma · Peroxisome proliferator-activated receptor gamma agonist
- RegorafenibTyrosine-protein kinase ABL inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- DexamethasoneMyxoid liposarcoma · Glucocorticoid receptor agonist
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- PalbociclibCDK6/cyclin D1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- EfatutazonePeroxisome proliferator-activated receptor gamma agonist
- RidaforolimusSerine/threonine-protein kinase mTOR inhibitor
Phase 1 or earlier 11
- TopotecanMyxoid liposarcoma · DNA topoisomerase I inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- RomidepsinHistone deacetylase inhibitor
- NelfinavirHuman immunodeficiency virus type 1 protease inhibitor
- CyclophosphamideMyxoid liposarcoma · DNA inhibitor
- ToripalimabProgrammed cell death protein 1 antagonist
- AlrizomadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- SiremadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- SeclidemstatMyxoid liposarcoma
- TP-1287
- BTX-A51
How its trials ended
136 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 24% met their primary endpoint, 14% missed it and 62% stopped early.
- Ongoing5540%
- Completed, result not reported3425%
- Stopped: other or unclear1310%
- Status unknown107%
- Met its primary endpoint97%
- Stopped: sponsor or business decision64%
- Missed its primary endpoint54%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
| Nov 16, 2023 | A phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (bi 907828) treatment in patients with treatment-naïve…Brigimadlin (bi 907828) | Boehringer Ingelheim (Canada) Ltd Ltee | Closed |
| Feb 11, 2022 | Brightline-1: a phase II/III, randomized, open-label, multi-center study of brigimadlin (bi 907828) compared to doxorubicin as first line treatment of patients…Brigimadlin (bi 907828) | Boehringer Ingelheim (Canada) Ltd Ltee | Closed |
| Aug 20, 2021 | A randomized multicenter phase 3 study of milademetan versus trabectedin in patients with dedifferentiated liposarcomaMilademetan (RAIN-32) | Rain Oncology | Closed |
| Jul 30, 2019 | A phase 2 single arm open-label clinical trial of ADP-A2M4 spear t cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma (spearhead…ADP-A2M4 | Uswm CT, LLC | Ongoing |
| Nov 20, 2015 | A phase 2-3 multicenter, randomized, double-blind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated…Selinexor (KPT-330) | Karyopharm Therapeutics | Ongoing |
| Dec 22, 2014 | A phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcomaSiremadlin (HDM201)/ Ribociclib (LEE011) | Novartis Pharmaceuticals | Closed |
| Jan 28, 2016 | HalavenTreatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen | Eisai Inc. | Approved |
| Oct 23, 2015 | YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing… | Janssen Research & Development, LLC | Approved |
| Mar 21, 2023 | N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-…Treatment of Liposarcoma | Shanghai Pharma Biotherapeutics USA Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA